Image via BioCentury
Last updated
Incyte: Ma Activity
Incyte acquiring Vega Therapeutics (Star Therapeutics' subsidiary) for $1.25B upfront plus up to $750M in milestone payments. Vega has Phase 3 bleeding disorder candidate.
Source: BioCentury
The leadership read
Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in the sector.
Market context: Backdrop: a 105.9 (Hot) Talent Market Index (down 2.3 on the month) with EMEA activity easing (-2.8pts).
Incyte: 2 signals in the last 90 days; 0.1% of MitchelLake's EMEA signal flow; 2 tracked across 28 days.
Also at Incyte →
More signals across EMEA
Ma Activity · EMEA
GE HealthCare →GE HealthCare spun off in early 2023 as independent healthcare equipment and services company; stock up 16% as standalone; strongly profitable
Ma Activity · EMEA
Electronic Arts (EA) →Saudi Arabia's Public Investment Fund (PIF) $55 billion acquisition of Electronic Arts has been approved under EU merger rules, completing a landmark deal in gaming/entertainment.
Ma Activity · EMEA
SkyCity Entertainment Group →SkyCity Entertainment has signed a deal to sell The Grand Hotel, indicating strategic portfolio optimization and potential capital redeployment
Ma Activity · EMEA
AI Digital →AI Digital acquired an in-house creative agency to expand its AI Creative Studio capabilities
Ma Activity · EMEA
Baker Hughes →Baker Hughes completed acquisition of Chart Industries and established dedicated Chart segment led by Jim Apostolides, reshaping industrial and energy technology operations
Ma Activity · EMEA
Tate & Lyle →Tate & Lyle accepted a £2.7bn takeover offer from US rival Ingredion in June 2026, following a 10% profit decline to £238m amid slowing consumer demand.
Intelligence powered by Autonodal ↗